Women's Health Research Topics Attracting Venture Funding

Venture capital in women's health used to be a rounding error. That's the whole story of this piece: money is finally showing up where the science has been waiting for it, and tracking where exactly it lands tells you which unsolved problems investors now believe are solvable.

For decades, women's health captured only about 6% of private healthcare investment, an oddly stubborn number given that women make up roughly half the population and use more healthcare services across their lifetimes than men do. Something changed, though, and it changed fast. Per SVB's 2025 Innovation in Women's Health Report, VC investment in the sector hit $2.6 billion in 2024, up from $1.7 billion in 2023, and up from around $400 million back in 2015. That's roughly a sixfold jump in under a decade, and the 55% year-over-year growth in 2024 actually outpaced the broader healthcare industry. Widen the lens to include diseases that affect women differently or disproportionately, and the 2024 total balloons to $10.7 billion, a figure that reframes the sector as considerably bigger than the niche label "women's health" usually implies.

W Group's narrower "pure-play" measure, which counts only dedicated women's health companies, tells a parallel and slightly more optimistic story: $1.55 billion in disclosed equity investment in 2025, up 41% from $1.1 billion in 2024, with 85 companies raising equity, the highest single-year count on record. So here's the puzzle worth sitting with before we go further: SVB's broader data shows a 2025 pullback, from $3.2 billion down to around $2 billion, while W Group's narrower data shows continued record-setting. Both are true, yet they're measuring entirely different things. That tension between "still record-breaking" and "still under 5% of global venture capital" is the frame for everything that follows.

How the composition of investment is shifting from consumer apps toward biopharma and clinical science

Early femtech, if you were paying attention around 2018 or so, was mostly period trackers and fertility apps: software wrapped around a calendar, sold to consumers who'd never had anything better. That mix has changed considerably. Per SVB, healthtech's share of women's health VC dropped from 54% in 2021 to 38% in 2024, while biopharma's share surged from 12% to 35% over the same stretch. Read plainly, that means investors are walking away from the software layer and toward companies solving actual clinical problems: drugs, diagnostics, therapeutics, the kind of thing where the competitive edge is a patent and years of trial data rather than a slicker onboarding flow.

Breadth is expanding right alongside that depth. In 2025, the ten rounds of $50 million or more spread across seven categories: oncology, fertility, maternal care, menopause, metabolic and GLP-1, sexual health diagnostics, and cross-category digital health, per W Group. The market as a whole now spans 15 clinical categories and more than 30 countries. This is no longer a U.S.-only story, and it reaches well beyond reproductive health alone.

Concentration is loosening too, which matters more than it might initially seem. In 2024, three companies, Flo Health at $200 million, Maven Clinic at $125 million, and Amber Therapeutics at $100 million, captured 39% of all equity invested in the sector. By 2025, the top three rounds accounted for just 32% of a larger total pool. In other words, fewer dollars concentrated in fewer companies, even as the total pool got bigger. What that tells you is the pipeline of fundable companies is widening: research areas that felt too early or too niche for institutional money two years ago are now reaching a stage where a serious check makes sense.

Menopause: from ignored life stage to investable market

Menopause has gone from a subject rarely discussed at a board meeting to the top-ranked femtech sub-sector by venture dollars, with $104 million raised in 2025 alone, per Dealroom, and one unicorn already minted. Dedicated menopause startups pulled in over $200 million across 2022 through 2025 combined, as investors woke up to a market of more than a billion women globally who have had, historically, almost nowhere good to go for care.

The investor thesis rests on two legs, and it's worth separating them because they get conflated a lot. First, market size: the menopause market was valued at roughly $17.8 billion in 2024 and is projected to keep growing through 2030. Second, economic urgency: the annual global economic impact of menopause, productivity loss plus healthcare costs combined, is estimated at $150 billion, according to SJF Ventures analysis. Layer onto that a newer wrinkle, the employer angle, where companies are starting to treat midlife workforce retention as a real cost center, which effectively creates a second payer beyond the individual patient.

Midi Health's $100 million Series D is the cleanest illustration of how that thesis actually converts into a check being written. Investors cited a $26.6 billion annual economic toll from menopause-related workplace attrition as part of their reasoning, per Forbes reporting, and Midi was reporting more than 25,000 patient visits a week at the time of the raise, which is the kind of number that turns a narrative into unit economics. The round pushed Midi past a $1 billion valuation.

Here's the part that's easy to miss if you only read the headline numbers: most of this capital has gone to care delivery, telehealth platforms, prescribing services, the front door of care. Comparatively little has gone to novel therapeutics, which leaves an obvious gap for the next wave of rounds. One tailwind worth watching is regulatory, since the FDA's increasing attention to hormone therapy evidence is reducing clinical uncertainty in a category that spent years mired in confusion left over from studies conducted decades ago, and that clarity tends to make biopharma investors more comfortable writing bigger checks.

Fertility and IVF technology: the category that has drawn the most capital over time

Fertility and IVF technology remains the single largest femtech category by a wide margin: approximately $811 million raised across 49 deals from 2022 through 2025, or 34% of total femtech capital in that window, per NewMarketPitch's analysis of PitchBook data. Why does fertility command such outsized checks? Because it changes what care actually produces, not just how it's delivered to the patient.

Reducing the hormonal injection burden of an IVF cycle, shortening that cycle, improving embryo selection accuracy: these are clinical improvements, and clinical improvements justify premium pricing in a way a nicer app never quite can. Fertility care platforms show a stronger ratio of capital share to deal share than most other women's health categories, meaning fewer deals capture more of the money, which is usually a sign that investors see a defensible technical edge rather than a crowded commodity market.

What's notable in 2025 is who's writing the checks. Bessemer Venture Partners invested in Pluro Fertility, while Peak XV, formerly Sequoia India, backed Luma Fertility. These are generalist firms, not fertility specialists, and their presence signals the category has crossed from a specialist interest into mainstream institutional territory. ReproNovo's 2025 raise, led by European healthcare investor Jeito Capital, adds a geographic dimension: fertility investing is globalizing, extending well past the U.S. market where a lot of early femtech stayed parked.

Gameto's Series B, backed by Two Sigma Ventures and RA Capital, points at where the R&D dollars are actually going: technology aimed at replacing hormonal injections altogether and shortening the IVF cycle itself. That's the frontier: reducing patient burden while improving outcomes at the same time. The unresolved tension in the category is access, since IVF remains limited by cost and geography for a huge share of people who need it, and the startups that figure out how to expand access, alongside polishing the premium tier further, represent the next wave of genuinely fundable ideas here.

Endometriosis: the diagnostic gap that investors are starting to price in

Endometriosis affects up to 10% of women of reproductive age globally, something like 190 million people, and 30 to 50% of those affected experience infertility, according to published research. Yet there are no approved disease-modifying treatments for it. A condition affecting one in ten women of reproductive age, and medicine's best answer for decades has been hormonal suppression or surgery, neither of which actually modifies the disease itself. Diagnosis delay, which averages years in most clinical settings, creates two distinct and separately fundable problems, a diagnostic gap and a therapeutic gap, and investors are starting to treat them as two different bets rather than one.

Endometriosis attracted $57 million in dedicated investment in 2025, per W Group. It's the largest single-year figure the category has ever seen, genuinely notable given how little attention endometriosis got for so long. That said, it remains a fraction of what the population burden would seem to justify, so this is still early-stage capital by any honest comparison.

On the therapeutic side, Gesynta Pharma's non-hormonal treatment program stands as the largest-ever therapeutic raise in the endometriosis category, and it's attacking a condition with zero approved disease-modifying drugs on the market. Non-hormonal matters here specifically because current hormonal suppression treatments carry real side effects and simply cannot be used by women trying to conceive, which carves out a large unmet-need population within an already large condition population.

On the diagnostic side, the NIH's RADx Tech ACT Endo Challenge, launched in August 2024 as a collaboration between NICHD and NIBIB, is focused on advancing non-invasive diagnostics, which functions as a kind of institutional stamp of approval that this is a solvable scientific problem rather than an intractable one. A 2024 University of Oxford clinical trial showed preliminary accurate detection of both superficial and deep endometriosis at early stages using a novel imaging technique involving the marker 99mTc-maraciclatide, the sort of early academic result that typically precedes VC attention by two to four years. For investors, the pitch here is asymmetric in a way that's rare: a large and precisely quantifiable affected population, near-zero existing pharmaceutical competition, and diagnostic innovation already emerging from academic labs. The runway is long, and that's exactly the point.

Women's oncology: where precision medicine and reimbursement clarity are converging

Women's oncology, breast, ovarian, and gynecological cancers together, ranks among the most investable femtech subcategories, per PwC's Future of Women's Health analysis, and the reasoning here is rooted in clinical differentiation more than sheer market size. Early detection in women's cancers produces measurable survival advantages, and measurable survival advantages translate directly into reimbursement, because payers have clear evidence in hand for what they're being asked to pay for. That clarity makes oncology diagnostics a more legible investment than categories where the reimbursement picture stays murky for years after the science is settled. Precision therapeutics, meanwhile, create genuinely defensible intellectual property, which is another reason generalist biopharma VCs gravitate here rather than staying on the sidelines.

A whole cohort of companies has raised institutional capital in women's cancer diagnostics: Mercy BioAnalytics, Clairity, PinkDx, AOA Dx, Teal Health, Vara, and BeSound. The breadth of that list matters, since it signals a genuine investment wave rather than one company getting lucky with a single big round. What's driving the early-detection push specifically is liquid biopsy and AI-based imaging, both of which are cutting the cost and invasiveness of screening enough that products can plausibly be used at scale instead of staying confined to specialized cancer centers.

Oncology also benefits, somewhat by inheritance, from the broader biopharma shift covered earlier: as capital in women's health moves toward clinical-stage companies generally, oncology is a natural landing spot, because it already has an established drug development playbook that investors know how to underwrite. The unresolved piece here is stark: ovarian cancer remains dramatically harder to detect early than breast cancer, and that gap is simultaneously a scientific challenge nobody's solved and a large stretch of whitespace for the next diagnostics company brave enough to try.

Cardiometabolic conditions and GLP-1: the emerging category that reframes who women's health investors are betting on

Cardiometabolic disease behaves differently in women than in men, with different symptom presentation and different risk trajectories, and for a long stretch of medical history, women were largely excluded from the foundational clinical trials that shaped how these conditions get treated at all. That combination created both a research gap and an investment gap, and the investment gap is only now starting to close.

GLP-1 therapies showed up among the seven categories represented in 2025's biggest rounds, the ones reaching $50 million or more, per W Group. That inclusion matters because it signals metabolic health in women can now attract mega-rounds, reaching well beyond scrappy early-stage bets nobody's watching. Why now, specifically? The blockbuster GLP-1 market broadly has created investor appetite for companies studying how these drugs behave differently in female physiology, dosing differences, side-effect profiles, interaction with hormonal cycles, questions that got skipped over in the initial rush to market. Cardiovascular disease, meanwhile, is the leading cause of death in women globally, and it remains systematically understudied in its female-specific presentation, a gap investors are starting to read as a commercial opportunity rather than just a public health failure. There's also a biological thread connecting this category back to menopause: post-menopausal cardiovascular risk accelerates through a specific, well-documented mechanism, which is likely one reason capital in both areas is climbing at the same time rather than independently.

What this represents, more than any single company or round, is a shift in who's paying attention. Cardiometabolic health in women pulls in the major cardiovascular and metabolic investors who historically never engaged with women's health as a sector at all. That said, it's still early, since the category lacks the named-company cohort and disclosed-round density that fertility or menopause can now point to, which makes it one of the higher-risk, higher-upside areas to watch in the next funding cycle.

What the geographic and stage distribution of deals reveals about where the field is heading

The sector now spans more than 30 countries, per W Group's 2025 report, and the global spread is not just a nice-to-know detail. It means clinical evidence and regulatory pathways are diversifying, which reduces the single-market concentration risk that used to make women's health investing feel riskier than it needed to be.

The femtech market globally drew $1.2 billion in 2024, about 20% more than in 2023, per PitchBook. Deal count actually fell slightly, though, from 160 to 154, a small number that tells a real story: capital is consolidating into fewer, bigger, later-stage rounds rather than spreading out to seed a wider crop of new startups. Average deal size backs that up, climbing from $11.6 million in 2022 to $24.3 million in 2024, before settling lower in 2025 as the mega-round pace normalized somewhat. That's a maturing market's trajectory, not a spike that's about to reverse.

The structural shift that matters most, though, is who's showing up to write checks. Bessemer, Two Sigma, RA Capital, Peak XV: none of these are women's health specialists by background, and their entry signals the category has crossed a credibility threshold where generalist limited partners are comfortable approving the mandate. When generalists show up, average check sizes tend to grow, later-stage rounds become genuinely available rather than theoretical, and the pipeline from Series A to exit gets more predictable for everyone downstream. Worth naming honestly: biopharma funding in the sector pulled back in 2025, from $1.3 billion to $610 million, per SVB, and that's a real number, not a footnote. It's largely explained by the macro rate environment and a broader biopharma funding contraction that hit far beyond just women's health, so read it as cyclical rather than structural. The number that probably matters more for judging where this field is actually headed is the 85 companies that raised equity in 2025, the highest single-year count ever recorded. Regardless of what any one year's total dollar figure does, that's the pipeline, and the pipeline is wider than it's ever been.

Why the remaining gaps, not the funded categories, tell the real story

The categories getting funded, menopause, fertility, oncology, cardiometabolic, all share something in common: they've reached a point where the science is legible enough, the market size is quantifiable enough, and the reimbursement or exit path is clear enough that a venture investor can build a model around them. That's genuinely good news, and it's worth not undercutting it. But it also means the funding map is, almost by definition, a map of what's already become easy to underwrite, and a separate question entirely from where the biggest unmet need necessarily sits.

Consider what's still thin on this list. Ovarian cancer detection remains a scientific problem nobody's cracked, sitting right alongside a breast cancer diagnostics field that's comparatively crowded. Autoimmune conditions that disproportionately affect women, lupus among them, barely register in any of the deal data cited above. Chronic pain conditions tied to reproductive health beyond endometriosis specifically haven't attracted anything close to a comparable wave. Access, too, the plain fact that premium fertility care and premium menopause telehealth mostly reach women who can already afford good healthcare, is a gap that shows up in nearly every category covered here without yet showing up as its own line item in anyone's funding report.

That raises a question worth sitting with rather than answering too quickly: is venture capital actually closing the underinvestment gap in women's health, or is it doing something narrower, funding the parts of that gap that happen to be commercially tractable right now, while the parts that are scientifically hard or economically inconvenient stay exactly where they've always been? Both things can be true at once, and the data laid out across this piece suggests they are. Under 5% of global venture capital still goes to women's health as a whole, even in a record year for pure-play companies. The money has arrived, and the interesting story is watching, category by category, which problems it decided were finally worth solving, and noticing, just as carefully, which ones it walked past.